Back to top

Image: Bigstock

Compared to Estimates, Ashland (ASH) Q3 Earnings: A Look at Key Metrics

Read MoreHide Full Article

Ashland (ASH - Free Report) reported $463 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 14.9%. EPS of $1.04 for the same period compares to $1.49 a year ago.

The reported revenue represents a surprise of -1.15% over the Zacks Consensus Estimate of $468.37 million. With the consensus EPS estimate being $1.15, the EPS surprise was -9.57%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Ashland performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Revenue- Intermediates: $33 million versus the two-analyst average estimate of $34.81 million. The reported number represents a year-over-year change of -8.3%.
  • Revenue- Specialty Additives: $131 million versus $123.73 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -12.7% change.
  • Revenue- Personal Care: $147 million versus the two-analyst average estimate of $146.57 million. The reported number represents a year-over-year change of -16%.
  • Revenue- Life Sciences: $162 million versus the two-analyst average estimate of $169.65 million. The reported number represents a year-over-year change of -16.9%.
  • Adjusted EBITDA- Life Science: $54 million compared to the $55.16 million average estimate based on two analysts.
  • Adjusted EBITDA- Intermediates: $7 million compared to the $3.48 million average estimate based on two analysts.
  • Adjusted EBITDA- Specialty Additives: $26 million versus the two-analyst average estimate of $26.25 million.
  • Adjusted EBITDA- Personal Care: $41 million versus $43.05 million estimated by two analysts on average.

View all Key Company Metrics for Ashland here>>>

Shares of Ashland have returned +1.3% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.

See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Ashland Inc. (ASH) - free report >>

Published in